/
Psychedelics in Mental Health: Psychedelics in Mental Health:

Psychedelics in Mental Health: - PowerPoint Presentation

hanah
hanah . @hanah
Follow
66 views
Uploaded On 2023-07-28

Psychedelics in Mental Health: - PPT Presentation

Hope is on the Way Jennifer Allen LMFT ATRBC Psychedelics Your Brain On Drugs Politics meets science Government sponsored adds with scare tactics Why What is a drug What makes one a medicine and one a poison ID: 1012392

amp lsd drug mdma lsd amp mdma drug drugs brain life psychedelic therapy maps psilocybin study schedule psychedelics assisted

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Psychedelics in Mental Health:" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

1. Psychedelics in Mental Health:Hope is on the WayJennifer Allen, LMFT, ATR-BC

2. Psychedelics?!

3. Your Brain On DrugsPolitics meets science. Government sponsored adds with scare tactics. Why?What is a drug? What makes one a medicine and one a poison?

4. Remember these? Misinformation

5. Updated Research & technology and an Updated Message   . This image shows different sections of the brain, the top row on placebo and the bottom row under the influence of LSD. The orange and red areas indicate a greater amount of neural activity in the LSD group. Photograph: Imperial/Beckley Foundation 2016 David Nutt Imperial College SQ Online MRI MEETS LSD: THE FIRST BRAIN SCANS CONDUCTEDGRACE SAHYOUNIPsychedelics like LSD, psilocybin & mescaline:Do NOT cause brain damage Are NOT addictiveDO correlate with lower mental health problemsPsychedelics and Mental Health a Population Study, Krebs& Johanson, 2013

6. Yet…Current DEA Drug SchedulingSchedule I drugs = no currently accepted medical use and a high potential for abuse. Illegal Schedule II drugsSchedule III drugs= moderate to low potential for physical and psychological dependence. These are often perscription medsSchedule IV drugs Schedule V drugs= deemed safest

7. Current Schedule of Drugs Schedule I: heroin, LSD, marijuana, MDMA, methaqualone, psilocybin and peyoteSchedule II: Vicodin, cocaine, methamphetamine, methadone, Dilaudid, Demerol, OxyContin, fentanyl, Dexedrine, Adderall, and RitalinSchedule III: Products containing less than 90 milligrams of codeine per dose: Tylenol with codeine, ketamine, anabolic steroids, testosteroneScehdule IV: Xanax, Soma, Darvon, Darvocet, Valium, Ativan, Talwin, Ambien, TramadolSchedule V: Robitussin AC, Lomotil, Motofen, Lyrica, Parepectolin

8. Reality Check: Drug Harm ScaleTop 3 overall harm = Alcohol, heroin, crack cocaine6th tobacco, 8th Cannabis, 11th Ketamine, 16th Anabolic steroid 17th Ecstacy18th LSD 20th Mushrooms/PsilocybinTop4 for drug related mortalityHeroin, Alcohol, Cocaine and Tobacco

9. A Brief History of Psychedelic Drugs

10. Bicycle Day, Mussels and SerotoninAlbert Hoffman accidentally discovers LSD 2/15/1943.LSD and serotonin similarities stimulate theory of serotonin in brain. Neuroscience is born!Betty Tordhog (1953) discovers serotonin in cow’s brains through a study of mussels.

11. Similar Molecules

12. How Do theY Work? https://thethirdwave.com

13. How do they work? Increased connectivity.Parts of the brain that don’t usually speak to each other connect.

14. Psilocybin – “Magic Mushrooms”“teonanacatl” or flesh of the Gods Used by indigenous cultures – Mazotec in Mexico. In 50s, Maria Sabina shares with Gordon Wasson who reports experience in LIFE magazine.1959 Albert Hoffman synthesizes psilocybin1962 Good Friday Experiment = Mystical Experience can be prompted by PsilocybinPositive outcomes for end of life anxiety, depression, anxiety, OCD, nicotine & alcohol addiction .

15. Psilocybin Study with Cancer Patients51 Patient with life-threatening cancer.80% decreases in anxiety and depression & improvement in attitude, mood, relationship& spirituality TRAIT anxiety decreases!(Griffiths, et al. 2016)

16. Quality of Life and Death Acceptance

17. MDMA -AKA Ecstasy, Molly, 3,4methylenedioxymethamphetamine – synthesized in 1912 by Merk Lab, but not until 1960’s when its psychoactive qualities are realized by Sasha Shulgin.

18. MAPS-MultiDisciplinary Association for Psychedelic Studieshttps://youtu.be/6ClPE7lLqschttps://maps.orgRick Doblin founder MAPS Mission: developing medical, legal, and cultural contexts for the careful uses of psychedelics & marijuana

19. MDMA And PTSDTed talk of Rick Doblin – The Future of Psychedelic Assisted Psychotherapy

20. https://s3-us-west-1.amazonaws.com/mapscontent/research-archive/mdma/PTSDandMDMA.png from the MAPS website

21. MDMA – Assisted Psychotherapy

22. Psychedelic Assisted Therapy Annie and Micheal Mithoefer created the first manual for this from their MAPS studies with MDMA. This will serve as the standard for medical MDMA. Inner Healer is accessed

23. Competencies of a Psychedelic Psychotherapist Empathetic abiding presence; Trust enhancementSpiritual intelligence Knowledge of the physical and psychological effects of psychedelicsTherapist self-awareness Ethical integrityProficiency in complementary techniques Janis Phelps Director of the first certified psychedelic therapy and research program at California Institute for Integral Studies

24. BreakThrough Therapy Status and Expanded AccessBreakthrough therapy status of drug is a term from the FDA used when preliminary clinical evidence shows the drug to be better than anything else we have for serious or life-threatening conditions. The FDA will then speed up the process of development. Expanded Access granted by the FDA and allows for the use of an investigational new drug outside of a clinical investigation (study) for patients who have serious or immediately life- threatening disease or condition and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition.

25. Ketamine For TRD, suicidality, PTSD, OCD, chronic pain Glutamate antagonist Causes enhanced synaptic plasticityDifferent than classic psychedelics – dissociativeQuick acting but requires continued treatmentEsketamine IV breakthrough status 2013FDA approves Spravato (nasal spray) 2019Caution for addiction with self-administrationBest results are with Ketamine Assisted Therapywww.Ketaminetrainingcenter.com

26. What you don’t know, can hurt you. Education =Harm reduction

27. Healing minds, expanding consciousness- the ripple